News

02/11/2011 09:28:44 Intervacc completes successful horse vaccine study using Isconova's Matrix C™adjuvant

Intervacc is currently developing Strangvac®, a vaccine against the horse disease strangles which uses Isconovas Matrix C ™ adjuvant. Strangles is an infection caused by the Streptococcus equi bacteria which is a major problem for horses and horse-owners.

11/10/2011 11:34:14 Nobel Prize and the Immune System

Isconova is delighted that this year’s Nobel Prize in Physiology or Medicine highlights central cornerstones of adjuvanticity, i.e. the impact of innate immunity and the role of dendritic cells. Congratulations to late Professor Ralph M. Steinman, Professor Bruce A. Beutler and Dr. Jules A. Hoffmann from Isconova.

12/09/2011 13:00:00 Positive T-cell data with Isconova’s Matrix M™ in avian flu vaccine study

Today members of the PanFluVac consortium presented a poster with results from an avian flu vaccine study revealing strong T-cell data with Isconovas Matrix M™ at the European Scientific Working group on Influenza (ESWI) conference in Malta September 11-14. The phase I clinical PanFluVac study evaluated the safety and the immunogenicity of an avian flu vaccine adjuvanted with Matrix M™.

05/07/2011 14:32:58 Annual Report 2010

Isconovas Annual Report 2010 is available in English.

27/04/2011 17:07:14 Editorial published in Expert Reviews

Iscom technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation - Karin Lövgren Bengtsson, Bror Morein, Albert DME Osterhaus

13/04/2011 12:42:25 PanFluVac newsletter: European Commission Initiative for Better Immunisation

PanFluVac - An European Commission funded research consortium for development of efficacious vaccine formulation system for prophylactic control of influenza pandemics.

30/03/2011 14:45:43 News

Article published in UU Innovation magazine

08/03/2011 17:35:55 Summary of Year -end Report 2010

24/02/2011 09:34:59 Meet Isconova

During March 2011 Isconova will be presenting the company at several events. 21st of March Isconova will participate in the Life Science Investment Day Scandinavia 2011 organised by SwedenBIO. This meeting will be in English. In addition Isconova will also participate in the following Swedish language meetings: Stockholm Corporate Finance Life Science/Health Care Day 2011 in Stockholm March 9 and Stora Aktie- och Fonddagen i Uppsala 2011 March 22 which is a meeting organisered by the Swedish Shareholders’ Association.

10/11/2010 09:00:00 NASDAQ OMX welcomes Isconova to First North

NASDAQ OMX (NASDAQ: NDAQ) announces that trading in Isconova (ISCO) shares will commence today, November 10, on First North at NASDAQ OMX Stockholm.